Dr. Ilonna Rimm (Harvard Medical School '81) is a healthcare investor who provides strategic advice on raising early-stage capital. She can fully understand the biological science of an emerging company. Then she can organize and polish the science to present it in a way that is attractive to life science investors. She recently provided services to Immuneering Corp., who raised a Series A round of $20M in January, 2020, and a Series B round of $62M in January, 2021. Ben Zeskind, PhD MBA, the CEO of Immuneering, is an HBS alum. Ilonna's advisory skills were developed during twenty years of Financial Services work on the Buy and Sell side of public equity, the Buy side of private equity and in the pharmaceutical industry.
Industries
Biotech & Life Sciences, Healthcare, Medical Devices & Hardware, Bioinformatics, Mental Health
Can help with
- Accelerating the raise of Seed and Series A rounds of capital
- Interacting with healthcare investors
- Business plans
- Storytelling in healthcare
- "Big picture" issues in healthcare
- "Patient - Doctor" interactions in healthcare
